Evidence map›Paper›PMID 41659735›Full record

ReviewPhenomics (Cham, Switzerland)2025

Integrin α6 Targeted Tumor Theranostics.

Xinling Li, Kaili Xie, Qiaoli Wang, Jiacong Ye, Wenbiao Zhang, Jie Yang, Musheng Zeng, Guokai Feng

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Phenomics (Cham, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xinling Li *State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060 P. R. China.
Kaili Xie *State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060 P. R. China.
Qiaoli Wang *State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060 P. R. China.
Jiacong YeState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060 P. R. China.
Wenbiao ZhangState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060 P. R. China.
Jie YangState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060 P. R. China.
Musheng ZengState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060 P. R. China.
Guokai FengState Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060 P. R. China.ORCID 0000-0002-8251-291X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Integrins mediate cell adhesion and transmit cellular chemical and mechanical signals bidirectionally. Abnormal activation of integrin signals drives tumor initiation, invasion, metastasis, and therapeutic resistance. Therefore, integrins are ideal tumor theranostic biomarkers. Among the 24 known human integrins, the integrin αvβ3 has been the most intensively studied in tumor theranostics in the past 20 years. Here, we focus on the laminin receptors integrin α6β1 and α6β4, which consist of the α6 integrin subunit and either the β1 or β4 integrin subunit, respectively. Both of these proteins are overexpressed in many cancers, and their expression has been linked to poor prognosis in some cancers. Over the last decade, we and our collaborators have developed several types of integrin α6-targeted probes, including single-photon emission computed tomography (SPECT), positron emission tomography (PET), magnetic resonance imaging (MRI) and near-infrared fluorescent imaging (NIRF) probes, for the molecular imaging of tumors. Among them, an integrin α6-targeted SPECT probe has been proven to be safe and efficient for detecting breast cancer in the first-in-human pilot study. Moreover, we have developed integrin α6-targeted therapeutic strategies for the treatment of tumors. In this review, we highlight the latest progress in integrin α6-targeted tumor theranostics.

Indexed as

BiomarkerIntegrin α6Molecular ImagingTargeted TherapyTheranostics

Identifiers

PMID41659735
PMCPMC12881227

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.